MAXCYTE, INC.

MXCT

CIK 0001287098 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$7M
↓-16.0% -$1Mvs FY2024 (Q4)
Gross Profit
$6M
↓-11.3% -$722Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -21.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 8.30 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.15x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -16.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -207.2% · trend -32.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2M
investment in PP&E
Stock-based comp (TTM)
$9M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$203M
everything owned
Total liabilities
$31M
everything owed
Stockholders' equity
$171M
shareholder claim

Recent performance · 24 quarters

Revenue↓-16.0% -$1M
$7M
Net Income↓-7.4% -$859K
$-12M
Free Cash Flow↓-57.1% -$84K
$-231K
Operating Margin↓-35.1pts
-207.2%

Drill down